Products for Emerging Economies

Fyodor is developing diagnostics and medicines for the effective diagnosis and treatment of infectious diseases in emerging markets. Our flagship product – the Urine Malaria Test (UMT) – is a non-invasive, one-step dipstick assay, less than two years away from establishing a significant revenue stream in the multi-billion dollar malaria market. The UMT lets people know immediately if a fever is due to malaria or not, using only a few drops of urine, and because of its simplicity (no blood, no reagents, no equipment), can be performed in resource-constrained settings, enabling immediate targeted treatment. As the first non-blood based tool for at-home or point-of-need diagnosis of clinical malaria, the UMT, which currently demonstrates over 90% accuracy, has the potential to dominate malaria diagnosis in the next decade and to markedly impact the way malaria is diagnosed and treated worldwide. 

Urine Malaria Test (UMT)

Fyodor has developed a novel Urine-based Malaria Test (UMT) for the rapid diagnosis of malaria in persons with fever.

Learn More

Malaria in the blood cells

About Malaria

Malaria is the world’s most important tropical parasitic disease and a leading cause of death worldwide.

Learn More

Market Need

The World Health Organization (WHO) reported 216 million cases of malaria led to over 655,000 deaths worldwide.

Learn More